Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AstraZeneca to scoop up biotech TeneoTwo for up to $1.27 billion

By Brian Buntz | July 5, 2022

AstraZenecaAstraZeneca (LON:AZN) has announced it has entered an agreement to acquire TeneoTwo and its Phase 1 clinical-stage CD19/CD3 T-cell engager TNB-486.

The company will pay $100 million on deal closing to acquire all outstanding equity of TeneoTwo. In addition, AstraZeneca will pay an additional $805 million in milestone payments and another $360 million in potential milestone payments to TeneoTwo’s equity holders.

TeneoTwo is investigating TNB-486 as a potential therapy for relapsed and refractory B-cell non-Hodgkin lymphoma.

AstraZeneca believes TNB-486 can potentially treat B-cell hematologic malignancies such as diffuse large B-cell lymphoma and follicular lymphoma.

In 2017, AstraZeneca won FDA approval for Calquence (acalabrutinib) for mantle cell lymphoma. In 2019, acalabrutinib won an indication for chronic lymphocytic leukemia.

Acalabrutinib is an agammaglobulinemia tyrosine kinase inhibitor.

Conversely, TNB is a T-cell engager, a bispecific molecule designed to coax T-cells into identifying and destroying cancer cells.

“By redirecting the body’s natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes,” said Anas Younes, senior vice president of hematology R&D at AstraZeneca, in a statement. “We believe this innovative molecule, which was designed to optimize the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting.”


Filed Under: Oncology
Tagged With: AstraZeneca, TeneoTwo
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AstraZeneca/Daiichi-Sankyo
FDA approves Enhertu for HER2-low breast cancer
ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Olema Oncology
Olema Oncology’s OP-1250 could be a game-changing breast cancer drug
Merck in the Drug Discovery & Development Pharma 50
Merck halts Phase 3 Lynparza for futility

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50